CytomX Therapeutics, Inc. (CTMX) Financials
CTMX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 205.2 million | 252.6 million |
2023-09-30 | 221.2 million | 272.4 million |
2023-06-30 | 209.2 million | 294.2 million |
2023-03-31 | 234.6 million | 321.3 million |
CTMX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -22.2 million | 2.6 million |
2023-09-30 | -18.3 million | 1.2 million |
2023-06-30 | -25.7 million | 2.4 million |
2023-03-31 | 9.3 million | 2.4 million |
CTMX Net Income
No data available :(
CTMX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 174.5 million | - | 14.0 million |
2023-09-30 | 194.1 million | - | 15.1 million |
2023-06-30 | 180.9 million | - | 16.1 million |
2023-03-31 | 204.5 million | - | 17.1 million |
CTMX Shares Outstanding
CTMX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 266000 | 18.9 million | 7.8 million | 37000 |
2023-09-30 | 9000 | 16.4 million | 6.8 million | - |
2023-06-30 | 517000 | 20.7 million | 7.4 million | - |
2023-03-31 | 48000 | 21.2 million | 8.0 million | - |
CTMX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 26.6 million | 486000 |
2023-09-30 | 26.4 million | 1.4 million |
2023-06-30 | 24.7 million | 1.5 million |
2023-03-31 | 23.5 million | 1.5 million |
CTMX
Price: $5.13
52 week price:
Earnings Per Share: -0.01 USD
P/E Ratio: -10.20
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 865300
Ebitda: -10.5 millionMarket Capitalization: 142.9 million